Clinical Trials

30 enrolled

Tumor-Agnostic

Neoplasms

NCT05895370 2023-06-08

GI-HPVT-01

12 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT05798546 2023-04-04

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Phase EARLY_PHASE1 Unknown

21 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05649618 2022-12-14

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

42 enrolled

Phase EARLY_PHASE1 Unknown

Solid Tumor

NCT05648994 2022-12-13

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

30 enrolled

Solid Tumors

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

45 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01946373 2022-10-04

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

20 enrolled

Dermatologic

Melanoma

NCT05530200 2022-09-07

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

56 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

66 enrolled

Advanced Refractory Solid Tumors

NCT05122221 2022-06-28

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

GastrointestinalGynecologicHead & Neck

12 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms

NCT03374839 2022-05-06

Nivo-TIL

11 enrolled

Dermatologic

Melanoma

NCT05115500 2021-11-10

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

55 enrolled

Tumor-Agnostic

Carcinoma

NCT03778619 2020-07-28

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

9 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT01701479 2020-07-14

LTI

288 enrolled

CNS

Neuroblastoma

NCT03412526 2019-04-04

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

15 enrolled

Gynecologic

Ovarian Neoplasms

NCT02173093 2019-01-29

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

40 enrolled

CNS

Neuroblastoma

NCT03175705 2018-01-18

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

18 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03171220 2017-06-06

NRT-01

40 enrolled

Advanced Malignant Solid Tumor

NCT03044743 2017-05-02

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

GastrointestinalHead & NeckLymphoid

20 enrolled

Nasopharyngeal Carcinoma, Hodgkin Disease, Stomach Neoplasms, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02315118 2016-06-22

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

LymphoidOther hematologic neoplasm

18 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02771743 2016-05-24

Response-based Treatment of High-risk Neuroblastoma

54 enrolled

CNS

Neuroblastoma

NCT01274273 2014-12-02

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

118 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01462903 2014-11-24

A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors